Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1 Recruiting 36 enrolled C. Babis Andreadis University of California, Davis · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19).

Timeline

Start: 2020-09-11
Primary completion: 2026-10-31
Completion: 2026-10-31

Publications

Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	anti-CD19 CAR-T cells	Cell therapy	500000 cells/kg	—
Background	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Background	Fludarabine	Small molecule	30 mg/m2	Intravenous

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Summary

Timeline

Publications

Drugs

Indications